Article Text

Download PDFPDF
NICE and the Cancer Drugs Fund—2020 vision?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Cancer Drugs Fund (CDF) in England emerged during the 2010 general election when the Conservative Party was keen to show that it would not deny patients new cancer drugs. It was intended as a temporary measure, pending the introduction of a new pricing model that would require the NHS to pay a price for a drug that reflected its ‘value’ rather than an amount set by the drug company.1,2 Value-based pricing never materialised and by March 2015, £968 million had been spent by the CDF on 74,380 patients.3 This included drugs that did not meet the National Institute for Health and Care Excellence's (NICE) adjusted cost-effectiveness …

View Full Text